Protective human antibodies against Powassan virus
Journal of Virology · 19.05.2026 · 100 (5)
DOI: 10.1128/jvi.02105-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, erschienen am 19.05.2026. Verfasst von Georgia Fallon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Viral, Antibodies, Monoclonal, Antibodies, Neutralizing, Encephalitis Viruses, Tick-Borne. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Powassan virus (POWV) is a tick-borne orthoflavivirus that can cause severe neuroinvasive disease. There are no approved vaccines or therapeutics, and the incidence of POWV infection in humans is rising. Here, we isolated and characterized a panel of human monoclonal antibodies (mAbs) from a convalescent donor using single B-cell sorting with POWV EDIII and full-length E ectodomain as antigen bait. Binding and neutralization assays with both POWV reporter virus particles and an authentic strain identified multiple neutralizing mAbs that target distinct epitopes across the E glycoprotein, including EDIII lateral ridge/C-C' loop and non-EDIII regions. Four neutralizing mAbs were evaluated in a lethal mouse challenge, two of which conferred substantial protection. These findings define key targets of the human antibody response to POWV and highlight candidates for the development of human monoclonal antibody therapy for this emerging virus. IMPORTANCE Powassan virus is an emerging tick-borne orthoflavivirus with steadily increasing case numbers. With an approximately 10% case-fatality rate and no approved therapeutics or vaccines available, POWV represents a potential public health threat. Our results showing that human monoclonal antibodies can protect mice against POWV in a lethal challenge model provide a foundation for developing future effective immunotherapies against this virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
ORCID-Profile: Georgia Fallon, Stefanie P Muraro, Samuel Ailsworth, Sean Hui, Ryan J Malonis, Alexandra L Tse, Emily Happy Miller, Daved H Fremont, Jonathan R Lai
Förderung
- NIAID NIH HHS
- NIH HHS
- NCI NIH HHS
- ODCDC CDC HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Fallon, G., Muraro, S. P., Ailsworth, S., Hui, S., Malonis, R. J., Tse, A. L., Miller, E. H., Chandran, K., Fremont, D. H., Diamond, M. S., & Lai, J. R. (2026). Protective human antibodies against Powassan virus. Journal of Virology, 100(5). https://doi.org/10.1128/jvi.02105-25
Vancouver
Fallon G, Muraro SP, Ailsworth S, Hui S, Malonis RJ, Tse AL, et al. Protective human antibodies against Powassan virus. Journal of Virology. 2026;100(5). doi:10.1128/jvi.02105-25
BibTeX
@article{Fallon2026,
author = {Fallon, Georgia and Muraro, Stefanie P and Ailsworth, Samuel and Hui, Sean and Malonis, Ryan J and Tse, Alexandra L and Miller, Emily Happy and Chandran, Kartik and Fremont, Daved H and Diamond, Michael S and Lai, Jonathan R},
title = {Protective human antibodies against Powassan virus},
journal = {Journal of Virology},
year = {2026},
volume = {100},
number = {5},
doi = {10.1128/jvi.02105-25}
}
EUVIMED